adMare BioInnovations Appoints John DeLucchi, Martin LeBlanc, and Tim van Biesen to the Board of Directors

adMare BioInnovations Appoints John DeLucchi, Martin LeBlanc, and Tim van Biesen to the Board of Directors

Vancouver (BC), Montreal (QC), and Toronto (ON) (October 4, 2023) – adMare BioInnovations is pleased to announce the appointment of John DeLucchi, President & CEO of Madison Venture Corporation, Martin LeBlanc, Co-Founder and Vice-Chairman of CellCarta Biosciences, and Tim van Biesen, head of the Global Healthcare & Life Sciences practice at Bain & Company, to its Board of Directors. Mr. DeLucchi will serve as the Chair of the Finance, Audit & Investment Committee. These additions will bring to adMare a wealth of experience and strategic business acumen acquired in their extensive careers across a multitude of industries.

"Mr. DeLucchi, Mr. LeBlanc, and Dr. van Biesen's extensive global knowledge and experience in strategic direction and growth will be invaluable assets to our governance," said Mr. Paul Buron, Chair of adMare’s Board of Directors. "The leadership of these three new Directors will bring a new perspective to our pursuit of Canadian life sciences leading the world by building companies, building ecosystems, and building talent" added Gordon C. McCauley, President & CEO of adMare.

Mr. John DeLucchi is the President & CEO of Madison Venture Corporation, a diversified private company with global interests across multiple industries. Madison employs approximately 2,000 people in different markets in Canada and the US, and serves customers and clients primarily in Canada, the US, and internationally. Prior to joining Madison, Mr. DeLucchi was a partner with PwC for over 35 years, where he served both private and public clients in several industries with operations in Canada, the US, Europe, South America, Asia, and Africa. Mr. DeLucchi's expertise spans business strategy, governance, risk management, financial reporting, and mergers & acquisitions. He currently serves on the Board of Directors of Canuck Place Children’s Hospice and has a history of board leadership with Covenant House Vancouver, United Way of the Lower Mainland, and the BC Business Council.

Mr. Martin LeBlanc is the Co-Founder and was recently named Vice-Chairman of CellCarta Biosciences after serving as CEO for 16 years. Formerly known as Caprion Biosciences and headquartered in Montreal, CellCarta is a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Under Mr. LeBlanc’s leadership, the company has sustained strong organic growth, concluded 10 company mergers and acquisitions, and has been successively managed under the ownership of 4 leading healthcare private equity firms. Mr. LeBlanc earned his bachelor’s degree in economics, from the University of Moncton, prior to completing an M.A. in Economics and Politics, at Oxford University as a Rhodes Scholar.

Dr. Tim van Biesen is the Global Healthcare Practice head at Bain & Company. He has more than two decades of management consulting experience across the comprehensive healthcare sphere, spanning manufacturers, payers, providers, and services – with differential expertise in medical devices and pharmaceuticals. Before joining Bain & Company, Dr. van Biesen was a senior scientist in neuroscience research at Abbott Laboratories. He has published more than 30 papers in peer-reviewed journals, and he is an inventor on two patents covering four human genes. He received his MBA from the Kellogg Graduate School of Management, Northwestern University, and a Ph.D. and B.Sc. in Molecular Microbiology from the University of Alberta.  

adMare BioInnovations also extends its heartfelt appreciation to Dr. Helen Burt and Meena Ballantyne, who have retired from the Board of Directors. Dr. Burt has been an adMare board member since 2019, previously served on the Board of Directors for CDRD since 2017, and is acknowledged as a founder of CDRD. Ms. Ballantyne has served on the board since 2021. 

“I want to express my sincere appreciation for the remarkable contributions of Helen and Meena, who are retiring from our board. Their thoughtful insight, and dedication to our mission, have left an indelible mark on adMare. We are immensely grateful for their invaluable service, " remarked Paul Buron, Chairman of the Board of adMare BioInnovations.


Media Contact
Mounia Azzi
Vice President, Corporate Development
adMare BioInnovations

About adMare BioInnovations
With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare currently has 29 portfolio companies that have attracted $2.3 billion of risk capital, have a combined value of $4 billion, and have created over 1,000 jobs in Canada. For more information, please go to